For instance, IPH2102 was used to inhibit inhibitory signaling of NK cells by preventing inhibitory KIRs from binding to HLA-C of cancer cells, thus activating ADCC mechanisms to kill the cancer cells that had been marked with cetuximab during head and neck immunotherapy (91). The gene discussed is HLA-C; the disease is cancer.